XML 43 R34.htm IDEA: XBRL DOCUMENT
v3.22.2.2

REVENUES - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 7,042 | $ 7,421 | $ 19,892 | $ 20,061
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,928 | 5,509 | 13,622 | 14,002
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,101 | 1,031 | 3,378 | 3,559
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,013 | 881 | 2,891 | 2,500
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6,978 | 7,356 | 19,650 | 19,848
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,900 | 5,479 | 13,482 | 13,932
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,064 | 997 | 3,281 | 3,419
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,013 | 880 | 2,887 | 2,497
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,487 | 4,189 | 12,422 | 11,777
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,661 | 3,302 | 9,906 | 9,132
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 541 | 602 | 1,653 | 1,776
Total HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 285 | 285 | 863 | 869
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,766 | 2,276 | 7,472 | 6,094
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,286 | 1,875 | 6,088 | 4,926
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 278 | 254 | 807 | 707
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 201 | 147 | 577 | 461
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 43 | 64 | 142 | 189
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 28 | 56 | 73
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 21 | 31 | 76 | 104
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 5 | 10 | 12
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 500 | 433 | 1,335 | 1,227
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 444 | 355 | 1,152 | 994
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 42 | 92 | 128
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 36 | 91 | 105
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 600 | 744 | 1,764 | 2,123
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 502 | 576 | 1,441 | 1,633
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 71 | 100 | 220 | 306
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 27 | 68 | 103 | 184
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 374 | 399 | 1,077 | 1,148
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 276 | 275 | 763 | 773
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 86 | 112 | 278 | 336
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 12 | 36 | 39
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 42 | 98 | 139
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 22 | 28 | 68 | 94
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 11 | 23 | 33
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 7 | 12
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 30 | 67 | 102 | 310
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 24 | 55 | 77 | 268
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 5 | 12 | 18
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 7 | 13 | 24
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 130 | 130 | 388 | 394
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 86 | 251 | 261
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 40 | 41 | 126 | 125
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 3 | 10 | 8
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 34 | 45 | 153
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1 | 24 | 11 | 110
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 6 | 20 | 19
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 4 | 15 | 24
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 925 | 1,923 | 2,905 | 4,208
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 336 | 1,527 | 1,179 | 2,763
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 130 | 109 | 560 | 761
Veklury | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 458 | 287 | 1,166 | 684
Total HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 524 | 429 | 1,371 | 1,488
Total HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 283 | 224 | 745 | 809
Total HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 143 | 94 | 332 | 322
Total HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 98 | 111 | 294 | 357
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 45 | 83 | 163
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 8 | 14 | 27 | 63
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 5 | 13 | 24
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 26 | 43 | 76
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 455 | 332 | 1,161 | 1,155
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 241 | 173 | 629 | 649
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 131 | 77 | 288 | 234
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 84 | 82 | 244 | 272
Other HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 44 | 52 | 127 | 170
Other HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 37 | 88 | 97
Other HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 12 | 31 | 64
Other HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 3 | 7 | 9
Total HBV/HDV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 264 | 247 | 733 | 704
Total HBV/HDV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 131 | 104 | 311 | 275
Total HBV/HDV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 29 | 85 | 76
Total HBV/HDV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 106 | 114 | 337 | 353
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 228 | 208 | 622 | 589
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 129 | 103 | 306 | 266
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 9 | 27 | 25
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 90 | 96 | 289 | 298
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 22 | 26 | 69 | 85
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 1 | 4 | 8
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 7 | 17 | 22
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 18 | 48 | 55
Other HBV/HBD |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 14 | 13 | 42 | 30
Other HBV/HBD | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 1 | 1
Other HBV/HBD | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 13 | 41 | 29
Other HBV/HBD | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Total cell therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 398 | 222 | 1,040 | 632
Total cell therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 270 | 135 | 688 | 394
Total cell therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 111 | 78 | 308 | 213
Total cell therapy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 9 | 44 | 25
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 81 | 47 | 217 | 119
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 60 | 35 | 160 | 94
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 12 | 56 | 25
Tecartus | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1 | 0 | 2 | 0
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 317 | 175 | 823 | 513
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 210 | 100 | 528 | 300
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 91 | 66 | 253 | 188
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 16 | 9 | 42 | 25
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 180 | 101 | 485 | 262
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 139 | 100 | 379 | 261
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 38 | 1 | 98 | 1
Trodelvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 0 | 8 | 0
Total other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 200 | 245 | 693 | 777
Total other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 80 | 87 | 275 | 298
Total other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 75 | 84 | 244 | 270
Total other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 46 | 74 | 174 | 209
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 105 | 143 | 380 | 420
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 7 | 48 | 32
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 63 | 67 | 192 | 202
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 33 | 69 | 140 | 186
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 43 | 46 | 135 | 157
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 43 | 46 | 135 | 157
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 52 | 56 | 178 | 200
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 34 | 91 | 109
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 11 | 17 | 52 | 68
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 5 | 35 | 23
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 64 | 65 | 242 | 213
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 30 | 140 | 70
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 37 | 34 | 98 | 140
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 0 | $ 1 | $ 4 | $ 3

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |